We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

MINDRAY In-Vitro Diagnostics

As a global leader in in-vitro diagnostics, Mindray provides a wide range of efficient, reliable IVD solutions for la... read more Featured Products: More products

Download Mobile App

Cutting-Edge Cardiac Biomarker Assays Enhance Cardiovascular Diseases Care

By LabMedica International staff writers
Posted on 31 Oct 2023
Print article
Image: The new cardiac biomarker assays aim to improve care of cardiovascular diseases (Photo courtesy of Mindray)
Image: The new cardiac biomarker assays aim to improve care of cardiovascular diseases (Photo courtesy of Mindray)

Heart-related diseases, or cardiovascular diseases (CVDs), are the number one cause of death across the globe. Early detection is crucial for saving lives. Medical guidelines suggest using high-sensitivity troponin I (hs-cTnI) and NT-proBNP as critical markers for identifying possible Acute Coronary Syndrome (ACS) and heart failure. These markers are essential for quick diagnosis, evaluating risk, and guiding treatment. Now, two new cutting-edge hs-cTnI and NT-proBNP assays aim to enhance the diagnosis and management of CVDs.

Mindray (Shenzhen, China) and its subsidiary HyTest, a global leader in antibodies and antigens, have collaborated to create these new assays. HyTest has been recognized for its expertise in cardiac biomarkers and had its troponin complex designated as the international standard by AACC in 2004. Both of the newly developed assays have been validated by Wuhan Asian Heart Hospital in China and Hennepin Healthcare Research Institute in the United States, showing excellent clinical performance.

The hs-cTnI test from Mindray exceeds the minimum requirements for hs-cTn, achieving an impressive 93% detection rate in the range between LoD and the 99th URL. Additionally, it has an imprecision CV under 5% at the 99th URL, proving its high sensitivity, accuracy, and dependability for spotting heart muscle damage. Moreover, a diagnostic study focusing on a 0-2 hour timeframe, carried out at Hennepin Healthcare Research Institute, supports its efficacy in diagnosing and managing heart conditions within this critical period. On the other hand, NT-proBNP is a well-established marker for heart failure management. Mindray's NT-proBNP test shows a high level of accuracy with a CV of ≤5% and successfully minimizes the impact of 55 common heart medications, making it a reliable tool for the detection and management of heart failure.

"Through integrating HyTest's pioneering antibodies and research on cardiac biomarkers with Mindray's advanced reagent technology and platform, we will deliver more reliable solutions that bring improved patient outcomes in the field of cardiovascular diseases and beyond," said Dr. Jianwen He, Chief Scientific Officer of Mindray IVD.

Related Links:

Platinum Supplier
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Gold Supplier
Pipette Controller
Sapphire MaxiPette
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Universal Laboratory Centrifuge

Print article


Clinical Chemistry

view channel
Image: A module with eight micro-devices, complete with microfluidic channels and drive motors (Photo courtesy of U.S Department of Energy)

Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses

Understanding the acidity or alkalinity of substances through pH measurement is crucial in many fields, from environmental monitoring to healthcare product safety. In many cases, these measurements must... Read more


view channel
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)

First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC

Sepsis, a critical medical condition that arises as an extreme response to infection, poses a significant health threat. It occurs when an infection triggers a widespread inflammatory response in the body.... Read more


view channel
Image: PointCheck is the world’s first device for non-invasive white cell monitoring (Photo courtesy of Leuko Labs)

World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. These cells play a crucial role in warding off infections.... Read more


view channel
Image: Current testing methods for antibiotic susceptibility rely on growing bacterial colonies in the presence of antibiotics (Photo courtesy of 123RF)

Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating... Read more


view channel
Image: AI methods used in satellite imaging can help researchers analyze tumor images (Photo courtesy of Karolinska Institutet)

AI Approach Combines Satellite Imaging and Ecology Techniques for Analysis of Tumor Tissue

Advancements in tumor imaging technology have significantly enhanced our ability to observe the minute details of tumors, but this also brings the challenge of interpreting vast amounts of data generated... Read more


view channel
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.